



# Yap1 Hydroxylation Suppress Prostate Cancer Metastasis

Ming Zhu<sup>1</sup>, Ruiqing Peng<sup>1,2</sup>, Xin Liang<sup>1</sup>, Zhengdao Lan<sup>3</sup>, Ming Tang<sup>4</sup>, Pingping Hou<sup>3</sup>, Jian H Song<sup>1</sup>, Celia Sze Ling Mak<sup>1</sup>, Jiwon Park<sup>1</sup>, Shui-Er Zheng<sup>1</sup>, Ailing Huang<sup>1</sup>, Xingdi Ma<sup>3</sup>, Ruidong Chen<sup>1</sup>, Qing Chang<sup>4</sup>, Christopher J Logothetis<sup>1</sup>, Abhinav K Jain<sup>5</sup>, Sue-Hwa Lin<sup>1,6</sup>, Hiroyuki Katayama<sup>7</sup>, Samir Hanash<sup>7</sup>, Guocan Wang<sup>1,8</sup>


<sup>1</sup> Department of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. <sup>2</sup> Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. <sup>3</sup> Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. <sup>4</sup> Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. <sup>5</sup> Department of Epigenetics and Molecular Carcinogenesis & Epigenomics Profiling Core Facility, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. <sup>6</sup> Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. <sup>7</sup> Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. <sup>8</sup> Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

## Abstract

Yes-associated protein 1 (YAP1), a key transcriptional coactivator in the Hippo pathway, is an important driver in cancer development and progression (1). It plays an oncogenic role in various cancer types. However, multiple studies also support a tumor-suppressive function for YAP1 (2-8). Thus, the functions of YAP1 are likely context-dependent (9). On the cellular level, YAP1 promotes prostate cancer cell proliferation (10-13). Yet, the role of YAP1 in prostate cancer cell invasion, migration, and metastasis is not well defined. Through functional, transcriptomic, epigenomic, and proteomic analyses, we showed that prolyl hydroxylation of YAP1 plays a critical role in the suppression of cell migration, invasion, and metastasis in prostate cancer (14). Knockdown (KD) or knockout (KO) of YAP1 led to an increase in cell migration, invasion, and metastasis in prostate cancer cells. Microarray analysis showed that the EMT pathway was activated in Yap1-KD cells. ChIP-seq analysis showed that YAP1 target genes are enriched in pathways regulating cell migration. Mass spectrometry analysis identified P4H prolyl hydroxylase in the YAP1 complex and YAP1 was hydroxylated at multiple proline residues. Proline-to-alanine mutations of YAP1 isoform 3 identified proline 174 as a critical residue, and its hydroxylation suppressed cell migration, invasion, and metastasis. KO of P4ha2 led to an increase in cell migration and invasion, which was reversed upon Yap1 KD. Our study identified a novel regulatory mechanism of YAP1 by which P4HA2-dependent prolyl hydroxylation of YAP1 determines its transcriptional activities and its function in prostate cancer metastasis.


## Results

### YAP1 Deletion/mutation is Associated with Poor Survival and Metastasis




**Figure 1. Yap1 deletion/mutation is associated with poor survival and metastasis.** (A) Disease free (Left) and Overall (Right) survival curve of patients with Yap1 WT or deletion/mutation. (B) Percentage of primary and metastatic tumors in patients with Yap1 WT or deletion/mutation.

### YAP1 Suppresses Cell Migration/Invasion and Metastasis




**Figure 2. Yap1 suppresses cell migration/invasion and metastasis.** (A, B) Cell migration and invasion assay using Plenti5m44-deficient prostate cancer (PS) cells transduced with control shRNA and Yap1 shRNAs. The Yap1 KD efficiency was confirmed by WB analysis. (C) Luciferase imaging in mice injected with PS cells transduced with control shRNA and Yap1 shRNAs through the tail vein.

### YAP1 Suppresses Pathways Involved in Cell Mobility and Metastasis




**Figure 3. YAP1 suppresses pathways involved in cell mobility and metastasis.** (A) GSEA analysis of microarray data from PS cells transduced with doxycycline-inducible Yap1 shRNA identified EMT as the top pathway activated in Yap1-KD cells. (B, C) ChIP-seq analysis identified YAP1 binding sites and YAP1-regulated pathways.

### YAP1 Interacts with P4HA2




**Figure 4. YAP1 interacts with P4HA2.** (A) Immunoprecipitation-mass spectrometry analysis identified known YAP1-interacting proteins and novel YAP1-interacting proteins. (B) Exogenous YAP1 interacts with endogenous P4HA2 when overexpressed in 293T cells by transfection of the indicated plasmids for co-immunoprecipitation experiments. (C) Endogenous YAP1 interacts with endogenous P4HA2 in PS cells.

### YAP1 is Hydroxylated at Multiple Proline Residues




**Figure 5. YAP1 is hydroxylated at multiple proline residues.** Multiple prolyl hydroxylation sites were identified in peptides of YAP1 isoform 3 from the LC-MS/MS analysis.

### YAP1 Hydroxylation-defective Mut4-5 (PA) Promotes Cell Migration/Invasion and Metastasis




**Figure 6. YAP1 hydroxylation-defective Mut4-5 (PA) promotes cell migration/invasion and metastasis.** (A) Scheme showing the strategy to generate prolyl hydroxylation-defective YAP1 mutants by mutating proline to alanine. (B) Expression of YAP1 WT and PA mutants in Yap1-KO PS cells. (C) Cell migration and invasion assay in Yap1-KO PS cells with overexpression of YAP1 WT and PA mutants. (D) Tail vein injection of Yap1-KO cells with overexpression of YAP1 WT and PA mutants.

### YAP1 P174 is Critical for Suppressing Cell Migration/Invasion




**Figure 7. YAP1 P174 is critical for suppressing cell migration/invasion.** (A, B) Cell migration and invasion assay using Yap1-KO PS cells with overexpression of GFP, YAP1 WT, Mut4-5, Mut4, and Mut5. (C) ChIP-qPCR analysis of YAP1, H3K4me3, and H3K9me4 binding sites in Col12a1 and Mgp.

### P4HA2 Suppresses Cell Migration/Invasion




**Figure 8. P4HA2 suppresses cell migration/invasion.** (A) WB analysis of P4HA2 in P4ha2-WT and P4ha2-KO PS cells. (B, C) Cell migration and invasion assay using P4ha2-WT and P4ha2-KO PS cells. (D) qPCR analysis of YAP1 target genes (Postn, Col12a1, and Mgp) in P4ha2 KO and WT cells.

### P4HA2 Suppresses Cell Migration/Invasion through YAP1



**Figure 9. P4HA2 suppresses cell migration/invasion through YAP1.** (A) WB analysis of YAP1 in P4ha2-WT and P4ha2-KO PS cells transduced with Yap1 shRNAs. (B) Cell invasion assay in P4ha2-WT and P4ha2-KO PS cells transduced with shYap1#434.

### Proposed Model for Tumor Suppressive Role of YAP1 in Metastasis



**Figure 10. Proposed Model for Tumor Suppressive Role of YAP1 in Metastasis.** A model for hydroxylation-dependent YAP1 function in cell migration, invasion, and metastasis. (Created with BioRender.com). Left: P4HA2-mediated hydroxylation of YAP1 may impair its interactions with transcription factors such as JUN or enhance the recruitment of corepressor, such as SWI/SNF-NCoR1, NuRD, and EZH2/YY1, which results in a decrease in the expression of genes involved in cell migration, invasion, and metastasis. Right: In the absence of P4HA2, non-hydroxylated YAP1 may efficiently interact with transcription factors such as JUN to activate genes involved in cell migration, invasion, and metastasis.

## References

- 1) Calses et al. *Trends Cancer*. 2019;5:297-307.
- 2) Eshani et al. *Oncogene*. 2010;29:160-71.
- 3) Yuan et al. *Cell Death Differ*. 2018;15:1752-9.
- 4) Yu et al. *Clin Cancer Res*. 2013;19:1389-99.
- 5) Metlitzky et al. *Mol Cell Biol*. 2007;27:962-75.
- 6) Cottini et al. *Nat Med*. 2014;20:599-606.
- 7) Levy et al. *Cell Death Differ*. 2007;14:743-51.
- 8) Cheng et al. *Cell Stem Cell*. 2020;27:590-604.
- 9) Ou et al. *Oncotarget*. 2017;8:75727-41.
- 10) Cheung et al. *Prostate Cancer Prostatic Dis*.
- 11) Nguyen et al. *Cancer Discov*. 2015;27:797-808.
- 12) Wang et al. *Cancer Discov*. 2016;6:80-95.
- 13) Zhang et al. *Mol Cell Biol*. 2015;35:1350-62.
- 14) Ming et al. *Oncogene*. 2021;40:6049-65.